蛋白酶体抑制剂对人工培养的细胞具有有效的抗肿瘤活性,通过降解受调控的促生长细胞周期蛋白来诱导肿瘤细胞的凋亡。这种可以选择性地诱导肿瘤细胞凋亡的方法被证明在动物模型以及人体试验中都非常有效。第一个获准临床试验和上市的蛋白酶体抑制剂硼替佐米,在治疗多发性骨髓瘤的患者中获得了较高的总体有效率和完全缓解率,这些显著的临床效果同时也激励着科学工作者们不断地向新的领域研究和探索。 Proteasome inhibitors have an effective anti-tumor activity on cultured cells, and induce apoptosis of tumor cells by degrading the regulated growth-promoting cyclin. This method, which can selectively induce apoptosis in tumor cells, has proved to be very effective in animal models as well as in human trials. The first clinical trial and marketed proteasome inhibitor, bortezomib, achieved a high overall response rate and complete remission rate in patients with multiple myeloma. These significant clinical effects also motivate scientific work. The people are constantly researching and exploring new areas.